Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SinoMab BioScience Limited
中國抗體製藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 3681)

(1) RESIGNATION OF CHIEF FINANCIAL OFFICER AND (2) CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

The board (the "**Board**") of directors (the "**Director(s)**") of SinoMab BioScience Limited (the "**Company**") hereby announces that (i) Mr. Jianping Hua ("**Mr. Hua**") has tendered his resignation as the Chief Financial Officer of the Company to pursue other opportunities and will cease to be an authorised representative of the Company (the "**Authorised Representative**") under Rule 3.05 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") with effect from 1 December 2026 and (ii) Ms. Florence Wai Ki Lai ("**Ms. Lai**") has tendered her resignation as the Company Secretary of the Company (the "**Company Secretary**") with effect from 1 December 2026.

Both Mr. Hua and Ms. Lai have confirmed that they have no disagreement with the Board and there is no matter relating to their resignations that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board is pleased to announce that Mr. Cheng Man Kwong ("**Mr. Cheng**") has been appointed as the Company Secretary and an Authorised Representative with effect from 1 December 2026 to fill the vacancies resulting from the resignations of Mr. Hua and Ms. Lai. Mr. Cheng joined the Company on 18 November 2026 as Vice President — Finance, and will assume responsibility for certain finance, accounting and reporting functions previously overseen by Mr. Hua with effect from 1 December 2026.

The biographical details of Mr. Cheng are set out below:

Mr. Cheng is a fellow member of both The Hong Kong Institute of Certified Public Accountants and the Association of Chartered Certified Accountants and an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. He holds a Master Degree in Professional Accounting and a Bachelor's Degree in Accountancy, both awarded by the Hong Kong Polytechnic University. Also, he holds a Professional Diploma in Company Secretaryship and Administration awarded by the

Hong Kong Polytechnic (now known as the Hong Kong Polytechnic University). After graduation from the Hong Kong Polytechnic, Mr. Cheng joined Price Waterhouse (now known as PricewaterhouseCoopers) and his last position held with the firm was audit manager. He has over 30 years' experience in accounting, financial management, corporate governance and audit, and has held various managerial and senior positions, including company secretary, in companies listed on the Main Board of the Stock Exchange.

The Board would like to express its gratitude to Mr. Hua and Ms. Lai for their valuable contributions to the Company during their tenures of office and extends its welcome to Mr. Cheng on his new appointment.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 23 November 2026

As at the date of this announcement, the executive Director is Dr. Shui On LEUNG, the non-executive Directors are Ms. Xiaosu WANG, Ms. Lei XUE and Dr. Jianmin ZHANG, and the independent non-executive Directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE, Ms. Chi Sau Giselle LEE and Mr. Nan SHEN.